Semaglutide for weight loss in advanced interstitial lung disease: A Pilot Study

Brief description of study

The aim of the pilot study is to demonstrate feasibility and tolerability of semaglutide in patients with obesity and advanced ILD. 

Detailed description of study

Semaglutide is a antidiabetic medication that has been known to help with long-term weight-loss management. The aim is to see the tolerability of the medication in patients with ILDs to promote weight-loss for feasibility of further pulmonary treatment. This is a 22-week study, during which you will be asked to work with the research study team and meet with them to complete research procedures. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Medical Research,Interstitial Lung Disease,Obesity
  • Age: Between 18 Years - 99 Years
  • Gender: All

- Diagnosis of an Interstitial Lung Disease
- BMI > 35 kg/m2
- Requires supplemental oxygen on exertion
- Semaglutide prescribed by primary pulmonologist
- Insurance approval

Updated on 09 Mar 2024. Study ID: 851742

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center